WILMINGTON, Del. - Phreesia (NYSE:PHR), a company specializing in patient intake and engagement solutions, has announced the appointment of healthcare industry veteran Bob Glazer as a Strategic Advisor.
Glazer's extensive experience, including a 27-year tenure as CEO of ENT and Allergy Associates, is expected to enhance Phreesia's services to meet the changing needs of healthcare providers.
During his time at ENT and Allergy Associates, which is the largest practice of its kind in the United States, Glazer oversaw significant growth, expanding the provider base from 12 to 250 and increasing the number of locations to over 50 across New York and New Jersey. His expertise in physician recruitment, revenue cycle management, and strategic planning is anticipated to be a valuable asset to Phreesia.
Evan Roberts, Phreesia's COO, expressed enthusiasm about Glazer's new role, highlighting the valuable insights he brings from his direct experience with medical practices, particularly in the single-specialty sector. Roberts emphasized that Glazer's guidance would be instrumental in setting up practices for success.
Glazer, who also heads Glazer Business Advisors, is involved in advising physician groups on various business aspects, including development and revenue expansion.
He expressed his eagerness to contribute to Phreesia's mission, reflecting on his previous partnership with the company during his leadership at ENT and Allergy Associates. Glazer aims to support the next generation of physicians by helping them navigate new challenges, such as patient engagement and care delivery.
Phreesia is recognized for its role in patient activation, providing tools that enable patients to take a more active role in their healthcare. With approximately 150 million patient visits facilitated in 2023, the company's digital solutions are designed to enhance patient experience, drive efficiency, and improve healthcare outcomes.
This strategic advisory appointment is based on a press release statement from Phreesia.
InvestingPro Insights
As Phreesia welcomes Bob Glazer to their strategic advisory board, the company's stock reflects a dynamic market presence. According to InvestingPro, Phreesia's market capitalization stands at $1.22 billion, signifying its substantial size within the healthcare technology sector. Despite recent market challenges, with the stock experiencing a notable decline over the past week, six analysts have revised their earnings estimates upwards for the upcoming period, suggesting potential optimism in the company's future performance.
InvestingPro data indicates that Phreesia has not been profitable over the last twelve months, with a negative P/E ratio of -9.94, adjusting to -10.66 for the last twelve months as of Q1 2025. Nevertheless, the company has demonstrated robust revenue growth of 23.98% during the same period, pointing to an expanding market share and successful adoption of its patient engagement solutions. With a gross profit margin of 66.0%, Phreesia is effectively converting a significant portion of its revenue into gross profit, a positive indicator for operational efficiency.
While analysts do not anticipate the company will be profitable this year, Phreesia's strategic moves, such as bringing industry experts like Glazer on board, could be instrumental in navigating the competitive healthcare landscape. For investors and stakeholders, these insights, along with additional InvestingPro Tips available on the platform, can provide a deeper understanding of Phreesia's financial health and market position.
To explore further details and additional InvestingPro Tips, visit the dedicated page for Phreesia at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.